Company Encyclopedia
View More
name
Royalty Pharma PLC - CL
RPRX.US
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
4.514 T
RPRX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking47/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE11.52%B
    • Profit Margin32.55%A
    • Gross Margin98.01%A
  • Growth ScoreC
    • Revenue YoY3.70%C
    • Net Profit YoY-33.20%D
    • Total Assets YoY7.23%B
    • Net Assets YoY-6.22%D
  • Cash ScoreC
    • Cash Flow Margin307.19%C
    • OCF YoY3.70%C
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreC
    • Gearing Ratio50.27%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Denali Therapeutics shares are trading higher after the company and Royalty Pharma announced a $275 million synthetic royalty funding agreement.

    benzinga_article·
    US
    DNLI
    +5.84%
    US
    RPRX
    -1.14%
    benzinga_article·
    US
    DNLI
    +5.84%
    US
    RPRX
    -1.14%

    Denali Therapeutics Secures $275 Million Royalty Deal With Royalty Pharma

    Denali Therapeutics Inc. has partnered with Royalty Pharma plc in a $275 million synthetic royalty funding agreement for tividenofusp alfa, an investigational therapy for Hunter syndrome. Royalty Pharma will pay $200 million upon FDA approval and $75 million upon European approval by 2029. In return, they will receive a 9.25% royalty on worldwide net sales until a specified return multiple is reached.

    Reuters·
    US
    RPRX
    -1.14%
    US
    DNLI
    +5.84%
    Reuters·
    US
    RPRX
    -1.14%
    US
    DNLI
    +5.84%

    CFO Coyne Sells 69,582 ($2.8M) Of Royalty Pharma PLC [RPRX]

    CFO Coyne Terrance P of Royalty Pharma PLC sold 69,582 shares worth $2.8 million, as disclosed in a Form 4 filed with the SEC. The transaction was executed under a prearranged trading plan (10b5-1). Coyne's ending holdings are 690,142 shares. The Washington Service provides insider trading analysis and data services.

    Reuters·
    US
    RPRX
    -1.14%
    Reuters·
    US
    RPRX
    -1.14%

    Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

    Marshall Urist, EVP of Research & Investments at Royalty Pharma, reported the sale of common shares. The information was published by Royalty Pharma via the U.S. SEC's EDGAR system on December 3, 2025. This brief was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    RPRX
    -1.14%
    Reuters·
    US
    RPRX
    -1.14%

    Shareholder TPC RP 2021 LLC Files To Sell 65,832 Of Royalty Pharma PLC [RPRX]

    TPC RP 2021 LLC, a shareholder of Royalty Pharma PLC, filed a Form 144 with the SEC to sell 65,832 restricted shares on December 1, 2025, through Goldman Sachs & Co. This sale is executed under a prearranged trading plan (10b5-1).

    Reuters·
    US
    RPRX
    -1.14%
    Reuters·
    US
    RPRX
    -1.14%
    © 2025 Longbridge｜Disclaimer